COX-2 Use Should Be Limited, FDA Advisory Cmte. Member Furberg Says In NEJM
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug Safety & Risk Management Committee member Furberg advocates using lowest effective dose for short-term use when a COX-2 inhibitor is needed. Furberg's editorial in the New England Journal of Medicine was released on the eve of the COX-2 advisory committee meeting.
You may also be interested in...
FDA's Woodcock To Testify Before Senate Health Committee March 3
Janet Woodcock is one of two FDA representatives testifying at two days of hearings on issues related to drug safety; Sandra Kweder will testify March 1. Vertex Pharmaceuticals CEO Joshua Boger will present the pharmaceutical industry's point of view.
FDA's Woodcock To Testify Before Senate Health Committee March 3
Janet Woodcock is one of two FDA representatives testifying at two days of hearings on issues related to drug safety; Sandra Kweder will testify March 1. Vertex Pharmaceuticals CEO Joshua Boger will present the pharmaceutical industry's point of view.
Safety Studies Should Be Required To Retain Celebrex, Bextra Approval – Researcher
Revised approval standards for COX-2 inhibitors still in development should be extended to marketed drugs "as a condition of their retention of approval," Penn researcher FitzGerald tells FDA advisory committee. FitzGerald says Vioxx safety signal is a class effect, calls Pfizer's argument that it is restricted to rofecoxib an "off-target fantasy."